Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of the Clinical and Economic Impact of Adverse Events and Medication-related Toxicities Associated With Interferon (IFN) Treatment for Patients With Stage III Melanoma

NCT02794636 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02794636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02794636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of the Clinical and Economic Impact of Adverse Events and Medication-related Toxicities Associated With Interferon (IFN) Treatment for Patients With Stage III Melanoma
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
May 31, 2014
Completion date
November 30, 2015
Enrollment
436 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii melanoma